GC LabCell Taps Alliances In Bid For Lead NK Cell Position

Links With Artiva In US

After accumulating technologies to develop off-the-shelf, allogeneic NK cell therapies over the past decade, Korea's GC LabCell is now tapping into the global market as US partner Artiva begins clinical trials of its lead asset.

NK Cell
Lead NK Cell Therapy Pipeline Begins US Clinical Trials • Source: Shutterstock

Over the past decade, GC LabCell has grown into a cell therapy development specialist from being focused previously mainly on clinical laboratory services. The company, which is emerging as a leader in the field of natural killer (NK) cell biology, has been concentrating on optimizing NK cell production and therapeutic applications and believes it is now ready to compete with global rivals.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Cell Therapies

More from Advanced Therapies